Rumalaya tablets

ЛП-001182

Rumalaya

Tablets

Each tablet contains
Active ingredients:

Over-steamed extract from: Vitex negundo leaves, Tinospora cordifolia culms, Ocimum Sanctum intact plant, Eclipta alba intact plant, Withania Somnifera roots, Zingiber officinale rootstock, Dashamool root mixture.

Hibiscus abelmoschus L., сем. Malvaceae, Moringa pterygosperma Lam., сем. Moringaceae, Rubia cordifolia L.s.l., сем. Rubiaceae, Tinospora cordifolia L, сем. Menispermaceae, Tribulus terrestris L., сем. Zygophyllaceae, Vitex negundo L., сем.Verbenaceae, Ocimum sanctum L., сем. Lamiaceae, Eclipta alba Hassk., сем. Asteraceae, Withania somnifera L., сем. Solanaceae, Zingiber officinale Roscoe, сем. Zingiberaceae.

Excipients: magnesium stearate 3.0 mg, microcrystalline cellulose 65.5 mg, sodium carmellose 19.5 mg, colloidal silicon dioxide 3.0 mg, crospovidone 31.0 mg.

Round biconvex uncoated tablets of greenish brown color interspersed with lighter and darker color spots.

Anti-inflammatory agent.

М09АХ.

The medicinal product of plant origin Rumalaya tablets has an anti-inflammatory, anti-edematous, microcirculation-improving effect. The intake of Rumalaya helps to reduce swelling, relieve pain, relieve muscle spasm, and increase the range of joint motions. The combination of bioflavonoids improves microcirculation and normalizes metabolic processes in joints and muscles.

There are no data on the pharmacokinetics of the multicomponent agent of plant origin Rumalaya in the tablet pharmaceutical form. The agent activity is stipulated by the mutually reinforcing combined action of its components, which is typical for the plant medicines. As far as it is impossible to designate the agent activity to any single compound in full, the pharmacokinetic studies of multicomponent agents of plant origin, including Rumalaya tablets, are unrealizable.

Inflammatory and degenerative diseases of the musculoskeletal system: rheumatoid arthritis, osteoarthritis.

Hypersensitivity to the separate agent components.

Children under the age of 18.

The intake during the pregnancy and lactation period.

The agent intake during pregnancy and lactation period is contraindicated.

Peroral. 2 tablets TID after meals for 4 weeks. In case of dyspeptic symptoms, the agent dose can be reduced to 1 tablet TID.

The repeated therapy courses are possible on the doctor's recommendation.

The allergic reactions (pruritus, urticaria) are possible. The dyspeptic symptoms (nausea, diarrhea, a feeling of bitterness in the mouth), a transient increase in the activity of "hepatic" transaminases are possible.

If any of the listed in the instructions side effects are aggravated, or you notice any other unlisted in the instructions side effects, please inform your doctor.

There have been no reports of overdose cases during the agent intake till the present moment. The treatment in case of overdose is symptomatic.

By the discontinuation of Rumalaya tablets the withdrawal effect was not observed. The special measures are not required when one or more doses are missed. In case the patient misses one or more doses, the agent should be continued according to the prescribed in the instruction regimen without doubling the dose.
No special precautions are required when disposing of unused medicine.
To enhance the therapeutic effect, it is possible to use with Rumalaya cream in the form of a cream for external use simultaneously.

Tablets. 60 tablets in a high density polyethylene plastic vial with a screw cap. The vial neck is additionally tightened with aluminum foil applied by the company's trademark. Each vial with instructions for use is placed in a cardboard box.

In a dry place at a temperature of 10°C to 30°C.
Keep out of the reach of children.

3 years.
Do not use after the expiration date.

Available with a prescription.